“The new data highlights the potential of CAN10 in fibrotic lung diseases. There is a large medical need to treat this group of diseases, and we see a huge future opportunity in this field” said Göran Forsberg, CEO of Cantargia.

SSc-ILD and IPF are irreversible fibrotic diseases with a very high unmet medical need. The new data from human lungs show that IL1RAP is expressed on several cell populations involved in lung fibrosis pathology, including epithelial cells, immune cells and fibroblasts, the cell population largely responsible for the pathological deposition of the extracellular matrix proteins that builds up the fibrosis. Moreover, the percentage of IL1RAP positive cells was higher in lungs from patients with SSc-ILD and IPF compared to healthy lungs. Together, these data strengthen CAN10 as a novel strategy to counteract pathological signaling in patients with lung fibrosis.

The data was generated in collaboration with the group of Prof. Gunilla-Westergren Thorsson at Lund University and will be presented by Dr. Linda Elowsson as a poster with an associated oral presentation. After the conference, the poster will be available at www.cantargia.com

CAN10 is one of two clinical projects in the Cantargia pipeline. The CAN10 antibody has been designed for treatment of several autoimmune/inflammatory diseases. The ongoing phase I clinical trial initially investigates increasing levels of CAN10 as single dose administration in healthy subjects followed by studies of multiple dosing in participants with psoriasis. The primary endpoint relates to safety. Details on the trial can be found at https://clinicaltrials.gov/study/NCT06143371.